Optimal Mid‑Range Dose for Anemia Treatment

What is Epobiocrin 4000 IU?

Epobiocrin 4000 IU is a standardized dose of recombinant human erythropoietin (epoetin alfa), used to treat moderate anemia—especially in patients with chronic kidney disease (CKD), chemotherapy‑induced anemia, or chronic illness. Each sterile pre-filled syringe contains 4000 international units, allowing effective hemoglobin response with fewer injections than low-dose regimens.

When to Use Epobiocrin 4000 IU?

• Moderate anemia correction: when dosages of 2000 IU are insufficient.
• Weekly dosing convenience: 4000 IU once weekly often replaces 2000 IU twice weekly.
• Ideal for outpatient/home therapy: efficient dosing for body weights 60–80 kg.
• Intermediate alternative: useful for patients transitioning between low (2000 IU) and high (10000 IU) dosing.

Composition and Presentation

A single 0.5 mL Epobiocrin syringe contains:

• Active Ingredient: Epoetin alfa – 4000 IU
• Excipients: Sodium chloride, sodium phosphate buffers, polysorbate 20, and water for injection.

The solution is clear, preservative‑free, packed in individual sterile syringes for accuracy and patient safety.

Mechanism of Action

Epoetin alfa binds to erythropoietin receptors on erythroid progenitor cells, triggering cell proliferation and differentiation, increasing red blood cell count and oxygen-carrying capacity, thus alleviating fatigue and improving quality of life.

Indications for 4000 IU Dose

Epobiocrin 4000 IU is indicated when moderate anemia requires moderate correction:

• CKD patients with hemoglobin levels around 8–9 g/dL
• Oncology patients with partial response to low-dose EPO
• HIV-associated anemia patients with mild to moderate anemia
• Long-term anemia management to maintain target Hb between 10–11 g/dL

Dosage & Administration

Starting Regimen

• Initial dose: 4000 IU once weekly, subcutaneously or intravenously
• For faster correction, may split into 2000 IU twice weekly

Dose Adjustments

• Monitor hemoglobin every 2–4 weeks
• Adjust dose ±25% depending on Hb response
• Reduce frequency if hemoglobin exceeds 12 g/dL

Maintenance Therapy

Once hemoglobin is stable (10–11 g/dL), dosing can be reduced to Epobiocrin 4000 IU every 10–14 days or switched to 2000 IU twice weekly based on response and body weight.

Pharmacokinetics

• Subcutaneous half-life: ~24 hours, peak absorption in 12–18 hours
• Intravenous half‑life: ~6–8 hours, faster action but shorter duration
• Bioavailability: ~20% via subcutaneous route

Safety and Side Effects

Common Adverse Effects

• Hypertension (10–25%)
• Headache or dizziness
• Injection site discomfort or redness

Serious Risks

• Thromboembolic events, especially if hemoglobin increases too rapidly
• Rare antibody-mediated PRCA (pure red cell aplasia)
• Excessive/rapid Hb rise—minimize cardiovascular risks

Monitoring

• Regular hemoglobin checks (every 2–4 weeks)
• Blood pressure monitoring mandatory
• Assess iron status periodically; supplement iron if needed

Contraindications & Warnings

• Hypersensitivity to epoetin alfa or excipients
• Uncontrolled hypertension
• History of thromboembolic events or PRCA
• Use in pregnancy or breastfeeding only if clearly needed

Clinical Evidence – 4000 IU Efficacy

Clinical studies show that 4000 IU weekly dosing effectively raises hemoglobin by 1–2 g/dL within 4–6 weeks in CKD patients without increasing injection frequency. Oncology studies demonstrate similar efficacy in managing chemotherapy-associated anemia and reducing transfusion requirements.

The post Epobiocrin (Epoetin alfa) solution for injection, 4000 IU #5 appeared first on MeDank Online Shop.

Injection for Severe Anemia and ESA Responders

What is Epobiocrin 10000 IU?

Epobiocrin 10000 IU is a high-dose recombinant human erythropoietin (epoetin alfa) formulation used in the treatment of severe or refractory anemia, especially in patients with chronic kidney disease (CKD), cancer-related anemia, chemotherapy-induced anemia, or anemia in HIV therapy. Each sterile pre‑filled syringe is calibrated to contain 10,000 international units (IU) of epoetin alfa and is designed for injection either subcutaneously or intravenously under strict medical supervision.

Why Choose Epobiocrin 10000 IU?

• High efficacy in severe anemia: Ideal when lower doses fail to raise hemoglobin.
• Reduced injection volume: One syringe often covers multiple weekly doses for patients above 80 kg.
• Convenient for outpatient or home therapy: Fewer syringes and injections.
• Essential for ESA hyporesponders: Used when patients show minimal response to 2000–5000 IU.

Key Benefits and Applications

Epobiocrin 10000 IU addresses anemia related to:

• Chronic kidney disease, including hemodialysis and peritoneal dialysis patients
• Chemotherapy-induced anemia in oncology patients
• HIV-associated anemia, especially in zidovudine-treated patients
• Preoperative anemia to reduce transfusion needs
• Patients with ESA hypo-responsiveness needing higher dosage

Composition and Product Packaging

Each 0.5 mL Epobiocrin syringe contains:

• Active Ingredient: Epoetin alfa – 10000 IU (recombinant human erythropoietin)
• Inactive Ingredients: Sodium chloride, polysorbate 20, thermostabilizers, water for injection

The solution is clear and colorless, supplied in a single-use sterile syringe to ensure safe, accurate dosing.

Mechanism of Action

Epoetin alfa mimics the physiologic effects of erythropoietin produced by kidneys. By binding to erythropoiesis-stimulating receptors on immature red blood cell precursors in bone marrow, it activates intracellular pathways that lead to proliferation, differentiation, and maturation of erythroid cells. This results in increased red blood cell mass, improved oxygen delivery, reduced fatigue, and better overall functional capacity.

Indications for 10000 IU Dose

Severe or Symptomatic Anemia in CKD

For hemoglobin < 8 g/dL in dialysis or nondialysis patients, a 10000 IU dose is often used to achieve faster control of anemia and reduce transfusion dependence.

Chemotherapy-Induced Severe Anemia

In oncology patients with severe anemia and limited response to conventional lower doses, 10000 IU enables more efficient correction while reducing injection frequency.

ESA Hyporesponse or Resistance

Patients who fail to respond to 2000–4000 IU may require a dose escalation to 10000 IU under supervision.

Dosage and Administration Guidelines

Starting Dose

• Usually 10000 IU once weekly, injected subcutaneously
• For rapid correction, initial dose may be split into 5000 IU twice per week

Dose Monitoring

• Monitor hemoglobin levels every 1–2 weeks initially
• Target hemoglobin is 10–12 g/dL; reduce or pause dose if > 12 g/dL
• Adjust dose by ±25% based on response

Maintenance Therapy

Once target hemoglobin is reached, dosing frequency may decrease to 10000 IU biweekly or adjust to lower frequency based on weight and response.

Pharmacokinetics and Pharmacodynamics

Following subcutaneous injection, epoetin alfa absorption gradually occurs, with peak plasma levels at 12–18 hours. Elimination half‑life is ~24 hours. Intravenous bioavailability is higher but associated with shorter half‑life (~8 hours) and requires more frequent injections.

Side Effect Profile

Common Side Effects

• Elevated blood pressure – occurs in 15–30%
• Injection site reactions: mild pain, erythema
• Flu-like symptoms: fatigue, arthralgia

Serious Risks

• Thromboembolic events (DVT, PE, stroke), especially at high Hb levels
• Pure red cell aplasia (rare antibody-mediated PRCA)
• Severe hypertension requiring dose reduction

Contraindications and Safety Precautions

• Known hypersensitivity to epoetin alfa or any component
• Uncontrolled hypertension must be stabilized before using
• History of PRCA or thrombotic events
• Pregnancy and breastfeeding only if benefit outweighs risks

Key Clinical Trials Supporting 10000 IU Use

Multiple Phase III trials in dialysis and oncology patients have shown that once-weekly high-dose epoetin alfa (including 10000 IU) effectively increases hemoglobin by an average of 2–3 g/dL within 4–6 weeks. These doses were generally well tolerated; hypertension was the most notable adverse event.

The post Epobiocrin (Epoetin alfa) solution for injection, 10000 IU #5 appeared first on MeDank Online Shop.

What is Epobiocrin 2000 IU?

EPOBIOCRIN 2000 IU is a therapeutic preparation of recombinant human erythropoietin (epoetin alfa) designed to treat various types of anemia—especially anemia due to chronic kidney disease (CKD), chemotherapy-induced anemia, or anemia associated with HIV infection. Each pre-filled syringe contains 2000 international units (IU) of epoetin alfa in a sterile solution, intended for subcutaneous or intravenous administration under medical supervision.

Why Use Epoetin Alfa 2000 IU?

• Effective in CKD-related anemia: helps stabilize hemoglobin and reduce transfusion dependency in dialysis patients.
• Cancer therapy support: helps oncology patients maintain acceptable hemoglobin during chemotherapy.
• Improves energy and stamina: often restores vitality, reduces fatigue and improves quality of life.
• Preoperative anemia management: used before major surgeries to minimize blood transfusion needs.
• Supports HIV patients: especially useful with zidovudine-induced anemia.

Composition and Presentation

Each 1 mL pre-filled syringe of Epobiocrin contains:

• Active Ingredient: Epoetin alfa — 2000 IU (recombinant human erythropoietin)
• Inactive Ingredients: Sodium chloride, sodium phosphate monobasic, sodium phosphate dibasic, polysorbate 20, and water for injection.

The solution is clear, colorless, and free from visible particles. It is supplied in individual sterile syringes to ensure aseptic administration.

Mechanism of Action

Epoetin alfa acts by binding to erythropoietin receptors on erythroid progenitor cells in the bone marrow. This binding triggers intracellular signaling that promotes proliferation and differentiation of erythroid precursor cells into mature red blood cells (RBCs). The increase in RBC count improves oxygen delivery to tissues, alleviates symptoms of anemia such as fatigue, weakness, and dyspnea, and supports overall physical performance.

Clinical Applications of 2000 IU Dose

The 2000 IU vial or syringe dosage is typically used as a maintenance or starting dose in moderate anemia. When administered subcutaneously or intravenously, doses vary depending on body weight, baseline hemoglobin, and clinical response. It is favored for outpatient and home-use settings due to its convenient dosing and reduced injection volume.

Chronic Kidney Disease (CKD)

Patients with CKD, especially those not on dialysis, often develop anemia due to reduced endogenous erythropoietin production. Epobiocrin 2000 IU is often prescribed to:

• Elevate hemoglobin levels to target range (10–12 g/dL).
• Manage anemia symptoms such as fatigue and cognitive impairment.
• Reduce need for red blood cell transfusions.

Dosing typically starts at approximately 50–100 IU/kg three times weekly until hemoglobin response is observed, followed by dose adjustments to maintain stability.

Cancer‑and Chemotherapy‑Induced Anemia

Many oncology patients experience anemia as a side effect of chemotherapy. Epobiocrin can be used to:

• Reduce transfusion requirements.
• Maintain hemoglobin at safe and tolerable levels.
• Improve patient endurance and ability to complete chemotherapy cycles.

HIV‑Associated Anemia

Patients on zidovudine (AZT) therapy often develop anemia. Epobiocrin helps:

• Counteract zidovudine-induced bone marrow suppression.
• Maintain hemoglobin and reduce risk of dose reductions or treatment interruptions.

Dosage Recommendations

Epoetin alfa dosing requires careful adjustment and monitoring:

Initial Dosage

• Typically 50‑100 IU/kg body weight, administered subcutaneously or intravenously three times per week.
• For a 70 kg adult, this equals approximately 140,000 IU per week, often divided into doses.

Monitoring and Dose Adjustment

• Target hemoglobin: 10–12 g/dL. Exceeding 12 g/dL may increase risk of cardiovascular events.
• Adjust dosage in increments of 25% based on hemoglobin response every 2–4 weeks.
• Maintain dose if hemoglobin rises by 1–2 g/dL over four weeks. Decrease dose if hemoglobin rises too quickly.

Maintenance Therapy

• Once stable hemoglobin is achieved, switch to maintenance dosing (e.g., 25–50 IU/kg once or twice weekly).
• Continue regular hemoglobin monitoring (every 4‑6 weeks).
• Ensure adequate iron stores—supplement iron if ferritin <100 ng/mL or transferrin saturation <20%.

Pharmacokinetics

Epoetin alfa has characteristic kinetics depending on route of administration:

• Half-life: Approximately 4–6 hours after intravenous injection; about 24 hours after subcutaneous administration.
• Bioavailability: ~20% after subcutaneous injection compared to intravenous route.
• No cumulative accumulation: Serum concentrations remain stable with repeated dosing.

Side Effects and Safety Profile

Common Adverse Events

• Hypertension (especially in patients with pre-existing blood pressure issues).
• Headache and dizziness.
• Flu‑like symptoms (fever, chills, myalgia).
• Injection site reactions (erythema, pain).

Rare but Serious Risks

• Thromboembolic events (deep vein thrombosis, pulmonary embolism, stroke).
• Pure red cell aplasia (PRCA) in rare cases of anti‑epoetin antibody formation.
• Excessive hemoglobin rise may increase cardiovascular mortality.

Management & Monitoring

• Regular monitoring of hemoglobin levels every 2–4 weeks during dose adjustments.
• Monitor blood pressure and adjust antihypertensive therapy if needed.
• Iron status markers (ferritin, transferrin saturation) should be checked periodically.

Contraindications & Precautions

• Hypersensitivity to epoetin alfa or any excipient.
• Uncontrolled hypertension (blood pressure should be stabilized before starting therapy).
• Patients with active malignancy should be carefully evaluated, as zidovudine may influence response.
• Pregnant or breastfeeding women—use only if benefits outweigh risks and under medical supervision.

Special Patient Populations

Elderly Patients

Use caution in older adults, especially those with cardiovascular comorbidities; dose and hemoglobin targets should be conservative.

Children & Adolescents

Dosing is weight-based; pediatric data are limited, so therapy should be individualized and supervised by a pediatric hematologist.

Clinical Trial Evidence

Multiple clinical studies demonstrate that epoetin alfa (2000 IU dosage range) effectively improves hematologic parameters in CKD and chemotherapy-induced anemia. In randomized trials, patients receiving EPO demonstrated: reduced transfusion needs, improved fatigue scores, and better exercise tolerance, compared to controls. Safety signals included mild hypertension and rare thromboembolic events.

How to Administer Epobiocrin 2000 IU

1. Allow syringe to reach room temperature before injection.
2. Wipe injection site (abdomen or thigh) with alcohol swab; rotate sites.
3. Inject slowly; discard syringe after single use.
4. Store unused syringes refrigerated (+2–8 °C), do not freeze.

Self‑Administration Tips

• Follow healthcare provider instructions exactly.
• Use proper disposal containers for sharps.
• Keep track of injection dates to avoid missed or duplicate doses.

Drug Interactions

No direct drug interactions are known; however:

• Concurrent use of iron supplements may be required to optimize response.
• Anti-hypertensive therapy may be needed to manage elevated blood pressure.
• Caution with pro-coagulant drugs due to thromboembolic risk.

Storage and Handling

• Store refrigerated between +2 °C and +8 °C.
• Do not freeze or shake the syringe.
• Protect from light.
• Discard unused portion after puncture; do not reuse syringe.

Frequently Asked Questions (FAQ)

Can Epobiocrin be taken orally?

No, it must be injected subcutaneously or intravenously. The protein would be degraded in the digestive tract.

How soon will I see results?

Hemoglobin typically increases within 2–6 weeks of starting therapy, depending on baseline conditions and iron status.

Is blood pressure monitoring necessary?

Yes. Elevated blood pressure is a common side effect and should be managed appropriately.

Availability and Legal Status

Epobiocrin is a prescription-only medication, approved in many countries including European Union nations, UAE, India, and other regions. Availability and brand name may differ locally; purchasing should be done through licensed pharmacies or medical providers.

Summary

EPOBIOCRIN 2000 IU (epoetin alfa) is a critically important biologic for treating anemia due to CKD, chemotherapy, HIV infection, or surgical preparation. Its precise dosing (2000 IU), predictable pharmacokinetics, and documented clinical efficacy make it a mainstay in anemia management. Safe use requires medical oversight, regular hemoglobin monitoring, and appropriate iron supplementation.

If you’d like a PDF or styled web block version of this description, or additional sections (e.g. cost comparisons, patient testimonials, regulatory approvals), just let me know.

The post Epobiocrin (Epoetin alfa) solution for injection, 2000 IU #5 appeared first on MeDank Online Shop.

Composition

Each tablet of Nicetil contains 500 mg of L-Acetylcarnitine as the active ingredient. Other non-active components include microcrystalline cellulose, magnesium stearate, and silicon dioxide.

Description

Nicetil is a medication based on L-Acetylcarnitine, a biologically active form of L-carnitine that plays a vital role in cellular energy metabolism. It supports the transport of fatty acids into the mitochondria, where they are converted into energy. This mechanism makes Nicetil useful in various conditions associated with energy deficiency and metabolic disorders. Each box contains 30 tablets, each with 500 mg of the active substance.

Pharmacology

L-Acetylcarnitine contributes to efficient energy production, especially in tissues with high metabolic demand such as muscles and the nervous system. It also possesses antioxidant properties, helping to neutralize free radicals and reduce oxidative stress. Some research suggests its potential neuroprotective effects, which may benefit patients with cognitive decline.

Indications

Nicetil is indicated in the treatment of:

• L-carnitine deficiency states
• Peripheral neuropathies (including diabetic neuropathy)
• Age-related cognitive decline and Alzheimer’s disease (as adjunct therapy)

Contraindications

Do not use Nicetil if you are allergic to L-Acetylcarnitine or any other components of the formulation. It is also contraindicated in individuals with severe renal dysfunction.

Dosage and Administration

The standard recommended dose is 500 mg (1 tablet) twice daily. Tablets should be swallowed whole with water, with or without food. Dosage may be modified by a healthcare provider based on individual needs and clinical response.

Side Effects

Possible side effects include nausea, vomiting, abdominal discomfort, and diarrhea. Some users may experience restlessness, insomnia, or skin rash. If side effects persist or become bothersome, consult a medical professional.

Precautions

Before starting Nicetil, inform your doctor of any ongoing treatments, supplements, or chronic health conditions. Caution is advised during pregnancy, lactation, and in patients with seizure disorders.

Storage

Store at room temperature, away from moisture, heat, and direct light. Keep out of reach of children.

References

For further information on the clinical use and pharmacological effects of L-Acetylcarnitine, see:

[PubMed: Neuroprotective actions of Acetyl-L-carnitine]
[PubMed: Acetyl-L-carnitine in diabetic peripheral neuropathy]

The post Nicetil (L-Acetylcarnitine, 30 tabs × 500 mg) appeared first on MeDank Online Shop.

Manufacturer

• Produced by: Institute of Molecular Genetics (IMG), Russian Academy of Sciences.
• Country of Origin: Russia

Composition

• Each 3 ml vial contains:
  • Semax peptide (synthetic ACTH(4‑10) analogue) – 1% (10 mg/ml).
  • Excipients: sterile water, methylparaben, sodium chloride (for isotonicity).

Indications

Semax is a synthetic nootropic and neuroprotective peptide indicated for:

• Acute ischemic stroke support.
• Recovery of cognitive functions post‑TBI.
• Chronic cerebrovascular insufficiency (ischemia).
• Neuroprotection during brain surgery.
• Memory, attention, concentration enhancement in mild cognitive impairments.
• Prevention of stress‑induced mental fatigue in high‑stress scenarios.

Dosage and Administration

• Route: Intranasal only (drops).
• Dosage regimens:
  • Stroke: 3–4 drops per nostril, 4–6 times daily for 10 days.
  • Cognitive impairment: 2–3 drops per nostril, 2–3 times daily for 5–14 days.
  • Mental fatigue prevention: 1–2 drops per nostril, twice daily for 3–5 days.
• Technique: Tilt head slightly back, instill evenly into both nostrils.
• Course duration: Varies between 5 and 14 days depending on indication.

Pharmacodynamics and Mechanism of Action

Semax is a modified heptapeptide (Met‑Glu‑His‑Phe‑Pro‑Gly‑Pro) derived from ACTH(4‑7). It modulates melanocortin receptors, increases BDNF and TrkB receptor expression, enhances synaptic plasticity, boosts cerebral perfusion, and activates serotonergic and dopaminergic pathways. It exerts antioxidant, anti‑inflammatory, immunomodulatory, and neurotrophic effects without hormonal side effects. For reference, see this study.

Use in Sports

Semax is increasingly used off‑label by athletes seeking cognitive edge, enhanced focus, faster mental recovery, and reduced fatigue during training or competitions. Its ability to raise BDNF levels may aid in neuroplastic adaptation under high cognitive and physical stress. While not banned by WADA, use should be monitored by sports medicine professionals.

Clinical Studies and Evidence

Preclinical studies in rat models of chronic brain ischemia demonstrated that intranasal Semax significantly improved learning, short‑ and long‑term memory, and behavioral performance. See the full publication on ResearchGate.

In a clinical study of ischemic stroke patients, Semax administered in two courses (6000 μg/day over 10 days, with a 20‑day interval) increased plasma BDNF levels and improved rehabilitation outcomes. See this source.

Contraindications

• Hypersensitivity to Semax or excipients.
• Acute psychosis or severe psychiatric disorders.
• Severe renal or hepatic impairment (use with caution).
• Children under 7 years of age (1% solution).

Precautions and Warnings

• Monitor cognitive and neurological status during treatment.
• May cause mild nasal irritation; avoid driving or machinery if dizziness occurs.
• Consult healthcare provider if combining with other nootropics or neuro‑agents.

Adverse Effects

• Local: Nasal dryness, mild irritation, burning.
• Neurological: Headache, light dizziness, occasional irritability.
• Hypersensitivity: Rare allergic reactions such as rash or itching.

Drug Interactions

• No major drug interactions reported.
• May potentiate effects of other nootropic peptides (e.g., Selank) when co‑administered.
• Seek medical consultation before combining with psychiatric or CNS medications.

Pregnancy and Lactation

Use during pregnancy and breastfeeding is not recommended due to lack of safety data. Only consider if benefits outweigh potential risks, under medical supervision.

Overdose

In case of overdose, mild symptoms such as nasal irritation or headache may occur. These effects are generally self‑limiting. Supportive measures (hydration, rest) are usually sufficient.

Storage

• Store refrigerated at 2–8 °C; do not freeze.
• Protect from direct sunlight and humidity.
• Discard within 30 days after opening.
• Keep out of reach of children.

Patient Information

Patients must be educated on correct intranasal administration technique, expected therapeutic timeline, and signs of side effects. Report any unusual symptoms promptly. Use only under the direction of a qualified healthcare provider.

Summary

Semax 1% nasal solution is a centrally acting synthetic peptide with demonstrated neuroprotective and cognitive-enhancing effects in ischemic stroke, TBI, and stress models. Its mechanism includes upregulation of BDNF, modulation of immune and neurotransmitter systems, and promotion of cerebral perfusion. Limited but consistent clinical evidence supports its use in stroke rehabilitation. Athletes may benefit from improved focus and faster recovery, though medical oversight is essential. Semax is generally well-tolerated, with minimal side effects and no known addictive potential. Use in special populations or children requires medical supervision.

The post Semax 1% 3 ml. vial appeared first on MeDank Online Shop.

Composition

• Main active ingredient: Astragalus membranaceus extract (standardized polysaccharides).
• Inactive ingredients: Purified water, sodium chloride (solvent/stabilizer).

Pharmacological Action

Astragalus membranaceus is a traditional Chinese medicinal herb known for its broad spectrum of pharmacological actions, including immunostimulant, adaptogenic, anti-inflammatory, antioxidant, antiviral, and cardioprotective properties. It enhances T‑cell proliferation, increases macrophage and NK cell cytotoxic activity, modulates pro- and anti-inflammatory cytokines (e.g., IL‑2, IL‑6, TNF‑α, IFN‑γ), and regulates oxidative stress through upregulation of endogenous antioxidant enzymes like SOD and glutathione peroxidase. The key bioactive components responsible for these effects are Astragalus polysaccharides (APS), flavonoids, and saponins.

Indications

Astragalus injection is used as an adjunctive or supportive agent in the following conditions:

• Chronic fatigue syndrome and general physical exhaustion
• Cardiovascular disease, including viral myocarditis and heart failure
• Cancer immunotherapy to improve immune status and reduce chemotherapy-induced toxicity
• HIV/AIDS: to enhance immune function and reduce opportunistic infections
• Recurrent respiratory tract infections (upper and lower)
• Renal disorders including nephrotic syndrome (via podocyte protection)
• Adjunct to seasonal flu prevention and recovery

Contraindications

• Autoimmune diseases (e.g., lupus erythematosus, multiple sclerosis, rheumatoid arthritis), as immune stimulation could exacerbate symptoms.
• Pregnancy and breastfeeding – insufficient data on safety in these populations.
• Known hypersensitivity to Astragalus or any of the excipients.

Administration and Dosage

The dosage of Astragalus injection depends on the therapeutic goal and patient condition. Typical regimens include:

• Intramuscular injection: 2–4 ml once daily or every other day.
• Intravenous drip (diluted): 10–20 ml diluted in 250 ml normal saline, once daily for 10–20 days (commonly used in hospital settings for immunosuppression or myocarditis).

Treatment cycles may last 10–21 days, followed by rest periods.

Side Effects

Astragalus injection is generally well tolerated. However, possible side effects include:

• Mild gastrointestinal discomfort (e.g., nausea, bloating)
• Localized skin rash or allergic reaction at injection site
• Headache or dizziness (rare)
• Altered blood coagulation profiles in high doses or long-term use

Severe adverse events are rare and typically resolve upon discontinuation.

Drug Interactions

• May reduce the effectiveness of immunosuppressant medications (e.g., corticosteroids, cyclosporine).
• May enhance the effects of anticoagulants – monitor INR and bleeding risk.
• Can influence the outcomes of lab tests involving cytokine assays or immune parameters.

Overdose and Treatment

Signs of overdose include gastrointestinal distress, fatigue, hypotension, or immune overstimulation. Treatment includes cessation of therapy, monitoring of vitals, and supportive care.

Storage

• Store between 15–25°C (room temperature), away from sunlight and moisture.
• Do not freeze.
• Use immediately after opening the vial.
• Keep out of reach of children and pets.

Mechanism of Action

Astragalus polysaccharides (APS) are the main active constituents and exert immunomodulatory effects through:

• Stimulation of macrophage phagocytic activity
• Enhancement of lymphocyte proliferation and NK cell cytotoxicity
• Regulation of pro- and anti-inflammatory cytokines (e.g., suppression of TNF-α, IL-6 via NF-κB pathway inhibition)
• Antioxidant action through scavenging ROS and upregulating antioxidant enzymes
• Cardioprotective and renoprotective properties via regulation of oxidative stress and inflammation

Clinical Studies and Evidence

A 2025 meta-analysis of 14 randomized controlled trials demonstrated that Astragalus injection significantly improved clinical outcomes in patients with viral myocarditis, reducing cardiac enzyme markers (CK-MB, LDH) and improving ECG parameters. Qian et al., 2025

A systematic review published in the Journal of Traditional Chinese Medicine highlighted Astragalus as an effective adjunctive agent in cancer patients, improving immune profiles and reducing chemotherapy-induced leukopenia. Piao et al., 2014

Use in Special Populations and Sports

In sports medicine, Astragalus is gaining popularity due to its adaptogenic properties:

• Supports post-exercise recovery by reducing inflammation and oxidative stress
• May enhance endurance through mitochondrial support and fatigue resistance
• Useful in overtraining syndrome by stabilizing immune response and reducing cortisol impact

Note: While not on the WADA prohibited list, athletes should consult a sports physician prior to use, as some immunomodulators can alter biological passport data or raise doping concerns.

In elderly or immunocompromised populations, Astragalus can serve as a preventive immune booster, but dosage should be tailored individually.

Additional Applications

• Renal protection: Astragalus has been shown to protect renal tubular cells, reduce proteinuria, and improve creatinine clearance in early-stage nephropathy.
• Liver support: Some studies suggest hepatoprotective effects via antioxidant and anti-inflammatory mechanisms.
• Diabetes adjunct: May improve glucose tolerance and insulin sensitivity through AMPK activation and reduced oxidative stress.

Formulations and Availability

Astragalus injection is typically available in 2 ml, 5 ml, or 10 ml ampoules at 1–2 g crude drug equivalent per 10 ml. It is a prescription-grade preparation in China and parts of Asia and may be available via international pharmacies for integrative medical practices.

Summary

Astragalus (Injection) Solution is a scientifically supported herbal immunomodulator and adaptogen with wide-ranging benefits. From immune enhancement to organ protection and stress resilience, its bioactive constituents target multiple physiological systems. Clinical trials support its use in viral myocarditis, immune suppression, and fatigue-related conditions. Though generally safe, usage should be guided by trained medical professionals, especially in athletes or individuals with autoimmune conditions.

References

• Qian et al., 2025 – Meta-analysis on Astragalus in viral myocarditis
• Piao et al., 2014 – Review of Astragalus in integrative oncology

The post Astragalus (injection) – 10 ampoules appeared first on MeDank Online Shop.

Glialia 700 is an ultramicronized oral suspension containing palmitoylethanolamide (PEA) 700 mg plus luteolin 70 mg in 10 ml per dose. Packaged as a 200 ml bottle with dosing syringe, it is designed for sublingual or oral administration. The formulation is optimized for neuroinflammatory support.

Composition

• Palmitoylethanolamide (ultramicronized form) – 700 mg per 10 ml
• Luteolin (ultramicronized) – 70 mg per 10 ml
• Excipients: water, corn dextrin, microcrystalline cellulose, sodium carboxymethylcellulose, polysorbate 80, potassium sorbate, citric acid

Pharmacological Action

This co‑ultramicronized formulation (PEALUT®) enhances absorption and bioavailability. PEA is an endogenous lipid mediator that modulates microglia, mast cells, and astrocytes, restoring neuro-glial homeostasis by reducing neuroinflammation, oxidative stress, and peripheral sensitization. Luteolin adds strong antioxidant and anti-inflammatory support, stabilizing mast cells and inhibiting NF‑κB and MAPK pathways.

Indications

Glialia 700 is indicated as a supportive treatment in:

• Neurological-inflammatory disorders such as post-stroke, mild cognitive decline, Parkinson’s, early neurodegeneration
• Post-traumatic brain injury or transient ischemic attacks
• Neuroinflammation-associated mood disorders or post-viral syndromes
• Chronic neuropathic pain, fibromyalgia, or persistent brain fog (e.g., post-COVID‑19)

Dosage and Administration

Typical dosing is 10 ml (one syringe) administered sublingually or orally 1–2 times daily for 20–30 days, potentially extendable to several cycles based on clinical response. Shake bottle before use. Suitable for use via nasogastric or PEG in cases of dysphagia.

Side Effects

• Occasional mild gastrointestinal discomfort (e.g., bloating)
• Rare headache or fatigue
• Possible mild skin reactions in sensitive individuals

Contraindications

• Pregnancy and breastfeeding—insufficient safety data
• Known hypersensitivity to PEA, luteolin, or formulation ingredients

Precautions

• Use under medical supervision—especially in patients with severe hepatic or renal impairment
• Monitor for potential interactions with immune-modulating therapies

Interactions

May interact with antiplatelet or anticoagulant medications. Patients taking warfarin or similar agents should monitor coagulation status. May influence results of cytokine or inflammatory biomarker assays.

Overdose and Treatment

No specific overdose cases reported. Excessive intake may lead to nausea or gastrointestinal discomfort. Cease administration and provide supportive care as needed.

Storage

• Store at room temperature (15–25 °C), protected from light and humidity
• Retain bottle tightly closed; use within expiration date
• Keep out of reach of children

Mechanism of Action

PEA binds PPAR‑α and exerts anti-nociceptive and anti-inflammatory effects, reducing mast cell degranulation and microglial activation. Luteolin enhances neuronal resilience by inhibiting inflammatory transcription factors and promoting antioxidant defenses. Together, PEA and luteolin restore neuroglial balance and support neuroprotection and synaptic stability.

Clinical Studies and Evidence

A randomized controlled trial in patients with long‑COVID-related cognitive symptoms showed that oral administration of Glialia® (ultramicronized PEA‑Luteolin, 700 mg + 70 mg daily) significantly improved measures of cortical excitability (LICI) and cognitive function compared to placebo. Versace et al., PMC 2022

A systematic review and meta-analysis published in Biomolecules (2023) confirmed that CoUltraPEALut improves recovery of olfactory function in post-COVID olfactory dysfunction (PCOD), with better TDI score outcomes when combined with olfactory training versus training alone. Capra et al., 2023

Use in Special Populations and Sports

Athletes and individuals subject to high cognitive or physical stress may benefit from Glialia’s anti-inflammatory and adaptogenic effects, including faster recovery, reduced fatigue, and improved mental clarity. Although not on WADA prohibited list, use in competitive settings should be managed by sports medicine professionals due to potential immunomodulatory and biomarker interactions.

Additional Notes

Co-ultramicronized PEA and luteolin (PEALUT®) allow for enhanced bioavailability and clinical efficacy at lower doses compared to non-ultramicronized forms. Use in elderly or frail patients may aid resilience and support quality of life, particularly in cognitive decline and sensory dysfunction.

Summary

Glialia 700 is an evidence-based neuronal support formulation combining palmitoylethanolamide and luteolin in an ultramicronized delivery form. It addresses neuroinflammation, oxidative stress, and neuronal dysfunction common to various CNS-related conditions. Supported by clinical trials in post-COVID cognitive and olfactory recovery, it offers a well-tolerated adjunct in neurological support under medical supervision.

References

• Versace et al. (2022) – PEA‑Luteolin neurophysiological study
• Capra et al. (2023) – Meta‑analysis in post‑COVID olfactory dysfunction

The post Glialia 700 (Syrup, 200 ml) appeared first on MeDank Online Shop.

Description

Reactine is an over-the-counter second-generation antihistamine containing Cetirizine Hydrochloride, widely used to relieve symptoms of allergic rhinitis, urticaria (hives), and other histamine-mediated conditions. It is valued for its rapid onset, 24-hour duration, and improved tolerability relative to first-generation antihistamines.

Active Ingredient

Cetirizine Hydrochloride is a selective H₁ receptor antagonist, minimizing allergic symptoms such as sneezing, rhinorrhea, nasal and ocular itching, and skin urticaria. It is the active component in Reactine formulations, including tablets, chewables, and syrup.

Pharmacological Action

Cetirizine selectively inhibits peripheral histamine H₁ receptors, blocking histamine-mediated inflammatory responses. It exhibits minimal central nervous system penetration, reducing sedation risk. Cetirizine also demonstrates modest anti-inflammatory activity via inhibition of NF‑κB and modulation of eosinophil chemotaxis and cytokine release. Its high tissue binding to albumin (~93 %) and slow metabolism contribute to its prolonged effect.

Indications

Reactine (Cetirizine Hydrochloride) is indicated for:

• Seasonal allergic rhinitis (hay fever)
• Perennial allergic rhinitis
• Chronic idiopathic urticaria (hives)
• Allergic conjunctivitis (adjunct relief for itching and redness)
• Other histamine-mediated dermatoses or mild allergic conditions

Dosage and Administration

• Adults and children ≥6 years: 10 mg once daily.
• Children 2–5 years: Pediatric syrup 2.5–5 mg once daily, depending on weight.
• Pediatric chewables: Follow label dosing; usually 5 mg twice daily in children under 12.
• Renal impairment: Dose reduction to 5 mg daily for CrCl 11–31 ml/min or in elderly, per regulatory guidance.

Take with or without food. Usually dose strength is 10 mg tablet or equivalent in syrup.

Side Effects

• Drowsiness and fatigue (sedation rates ~10–15 %).
• Dry mouth common.
• Occasional headache, dizziness, or abdominal discomfort.
• Rare: urinary retention or palpitations.
• Very rare: pruritus after discontinuation (FDA warning May 16, 2025).

Contraindications

• Hypersensitivity to Cetirizine, hydroxyzine, or formulation components.
• Severe renal impairment without dose adjustment.
• Use during lactation generally not recommended; pregnancy category B (use if necessary).

Precautions

• Caution when driving or operating machinery due to possible sedation.
• Use in elderly or pediatric populations with reduced dosing and monitoring.
• Discontinuation after prolonged use may provoke severe itching (pruritus) — follow tapering recommendations.

Interactions

Cetirizine is not metabolized by CYP450 enzymes, meaning low risk of interactions with common medications that affect liver enzymes. However, caution is advised with:

• CNS depressants—may increase sedation.
• Anticholinergic medications—may exacerbate dry mouth or urinary retention.
• Lab interference—may affect immunoassay results or inflammatory biomarkers.

Overdose

Excessive ingestion may result in extreme drowsiness, tachycardia, or headache. Supportive care, monitoring of vital signs, and hydration are standard interventions. In children, monitor for excitation or sedation.

Storage

• Store at room temperature, away from moisture and heat.
• Do not freeze.
• Keep out of reach of children and pets.

Mechanism of Action

Cetirizine binds selectively to peripheral H₁ receptors, preventing histamine from producing allergy symptoms. It does not significantly penetrate the CNS, thus causing less sedation compared to first-generation antihistamines. The drug also exhibits modest inhibition of inflammatory mediators and mast cell stabilization.

Clinical Studies and Evidence

A large randomized controlled trial showed that Cetirizine 10 mg daily significantly reduces symptoms of seasonal allergic rhinitis and chronic urticaria compared to placebo and is well tolerated (Grant et al., 1995). Another network meta-analysis in 2023 confirmed cetirizine’s efficacy among H₁ antihistamines, with substantial symptom relief albeit slightly higher sedation risk than fexofenadine (Hong et al., 2023)

Use in Special Populations and Sports

Reactine is approved for children as young as 6 months (in syrup form), with demonstrated safety in pediatric allergic rhinitis. Use in elderly should consider renal clearance—dose adjustment required for CrCl <30 ml/min. For athletes, cetirizine is generally permitted by WADA but may cause sedation affecting performance or reaction time; caution advised before competitions.

Comparison with Other Antihistamines

Compared to loratadine and fexofenadine, cetirizine is similarly effective but may cause mild drowsiness more rapidly. It shows faster onset than fexofenadine and stronger urticaria suppression in clinical trials. Levocetirizine (L-isomer) may offer reduced sedation at lower doses.

Summary

Reactine (Cetirizine Hydrochloride) is a reliable, effective, and generally safe antihistamine medication for allergic rhinitis, hives, and related conditions. With once-daily dosing and a favorable safety profile, it is widely used in adults and children. Use should be tailored in renal impairment, and discontinuation should be managed to minimize withdrawal pruritus risk.

References

• Grant et al., 1995 – Cetirizine efficacy in allergic rhinitis
• Hong et al., 2023 – Comparative meta‑analysis of H1 antihistamines

The post Reactine (Anti-Allergy Medication) appeared first on MeDank Online Shop.

Composition

• Each ampoule contains: Inosine 400 mg in 10 ml solution.
• Solvent: sterile water for injection; isotonic agent: sodium chloride.
• No preservative or additives—clear, colorless sterile solution.

Description

Inosine Injection is a sterile nucleoside preparation in glass ampoules (5 × 10 ml). Inosine is a purine nucleoside integral to nucleotide metabolism and energy production. Following parenteral administration, Inosine is rapidly deaminated to hypoxanthine and xanthine, ultimately increasing serum urate levels—a biochemical pathway with implications for cellular metabolism, antioxidant defense, and purine salvage pathways.

Pharmacological Action

Inosine exerts multiple systemic effects: it serves as an energy substrate via ribose metabolism, supports ATP production, promotes coronary vasodilation, improves myocardial bioenergetics, and demonstrates neuroprotective and immunomodulatory effects. Inosine has been shown to stimulate axonal growth in experimental models, reduce inflammatory cytokine expression (TNF‑α, IL‑1β, IL‑12), and support effector T‑cell bioenergetics under glucose deprivation. It also acts as an intermediary in purine metabolism, raising serum urate—an endogenous antioxidant—though elevated urate may carry risks in certain contexts.

Indications

Inosine Injection is indicated for:

• States of metabolic exhaustion or high energy demand (e.g. post-surgery, chronic fatigue, recovery phase of illness)
• Adjunctive support in cardiac conditions with impaired perfusion or energy metabolism
• Patients undergoing high-intensity physical activity who require improved oxygen utilization
• Selected neurological conditions or immune-modulating support, under experimental or off-label use

Contraindications

• Known hypersensitivity to inosine or any component.
• Gout, hyperuricemia, or crystal-induced arthropathies—serum urate elevation contraindicated.
• Pregnancy and breastfeeding—safety not established.
• Not recommended in pediatric patients under supervision—insufficient evidence.

Dosage and Administration

• Administer intravenously over 10–15 minutes per ampoule (400 mg).
• Typical adult dose: 1 ampoule daily; do not exceed 2 ampoules (800 mg) per day.
• Adjust injection speed and dosage per patient tolerance and renal function.

Side Effects

• Occasional mild allergic reactions—rash, itching, urticaria.
• Nausea, vomiting, lightheadedness, tachycardia.
• Elevated uric acid levels—risk of gout, kidney stones, nephropathy.
• Rare cardiovascular or renal adverse events, typically reversible upon cessation.

Precautions

Monitor serum uric acid periodically—especially in patients with prior hyperuricemia or cardiovascular risk. Advise limiting purine-rich foods and alcohol during treatment. Monitor renal and hepatic function if long-term usage is considered.

Interactions

• Concomitant use with xanthine oxidase inhibitors (e.g., allopurinol) may alter uric acid metabolism.
• May affect assays for cytokines or inflammatory biomarkers.
• Monitor synergy or interference with antiviral or immunomodulatory agents.

Overdose and Treatment

Overdose symptoms may include nausea, hypotension, dysrhythmias, or altered consciousness. Management is supportive: cease inosine, hydrate, correct electrolytes, and monitor vitals. Urate-lowering therapy may be considered if hyperuricemia is severe.

Storage

• Store at room temperature (15–25 °C), protected from direct sunlight.
• Do not freeze.
• Keep ampoules in original sealed packaging; use promptly after opening.
• Keep out of reach of children.

Mechanism of Action

Inosine is converted to hypoxanthine and ribose-1-phosphate, supporting ATP generation through glycolysis and the pentose phosphate pathway. It promotes vasodilation and cardiac energy metabolism, suppresses pro-inflammatory cytokines, and supports nerve regeneration via NGF-related pathways observed in preclinical models.

Clinical Studies and Evidence

A randomized clinical trial (SURE‑PD3) demonstrated that orally elevated serum urate via inosine is generally safe and tolerated over up to 24 months, though increased rates of nephrolithiasis were observed (7 per 100 patient‑years vs 1.4 in placebo). Bluett et al., 2021

A safety trial (Iwaki et al., 2017) involving early Parkinson’s patients confirmed one-year oral inosine (≈1070 mg/day) safely raised uric acid from ~3.5 mg/dL to ~6.7 mg/dL without severe adverse events; transient crystalluria noted. Iwaki et al., 2017

Use in Special Populations and Sports

Athletes may use inosine IV for recovery after intense exertion; by supporting ATP generation and metabolism, it may alleviate fatigue. However, the increase in serum urate poses a risk for gout or renal stones. Not prohibited by WADA, but professional supervision and uric acid monitoring are recommended.

Elderly or cardiac patients should receive careful dosing and lab monitoring due to altered renal clearance and urate handling.

Additional Notes

Emerging research highlights inosine’s role in immune cell metabolism: T lymphocytes can metabolize inosine as an alternative carbon source under glucose deprivation, supporting effector function and enhancing anti-tumor immunity in vitro. Wang et al., 2020 Additionally, murine studies show that inosine administration increases energy expenditure and thermogenesis, suggesting potential metabolic benefits. Willemsen et al., 2022

Summary

Inosine Injection is a metabolically active nucleoside preparation delivering 400 mg per dose. It supports energy metabolism and has roles in cardiac, neurological, and immune support contexts. While generally well tolerated when administered under supervision, it elevates serum urate, posing risks for gout, nephrolithiasis, and renal function impairment. Monitoring is essential, especially in high-risk populations. In selected cases, its use may support recovery from exhaustion or metabolic stress, under the guidance of qualified healthcare professionals.

The post Inosine Injection (5 ampoules × 400 mg/10 ml) appeared first on MeDank Online Shop.

Composition

• Active ingredient: Phytomenadione (Vitamin K1) – 10 mg per 1 ml ampoule.
• Excipients: glycocholic acid, lecithin, sodium hydroxide, hydrochloric acid, water for injections.

Description

Konakion MM 10 mg is a clear, sterile yellow-brown solution for oral or intramuscular administration. It contains a micellar solution of fat-soluble vitamin K1 designed for enhanced absorption, even in patients with impaired bile production or fat malabsorption. Manufactured by Roche Pharmaceuticals, Konakion MM is typically supplied in 1 ml glass ampoules.

Pharmacological Action

Phytomenadione (vitamin K1) is a vital cofactor for hepatic synthesis of coagulation factors II, VII, IX, and X, as well as proteins C and S. Without adequate vitamin K1, the gamma-carboxylation of glutamic acid residues in these proteins is impaired, leading to dysfunctional clotting and increased bleeding risk. Konakion MM rapidly restores physiological levels of active vitamin K1, reactivating coagulation pathways and reducing haemorrhagic complications.

Indications

Konakion MM 10 mg is indicated for:

• Prevention and treatment of vitamin K deficiency bleeding (VKDB) in neonates and infants.
• Vitamin K deficiency due to chronic liver disease, biliary obstruction, or intestinal malabsorption.
• Hypoprothrombinaemia induced by long-term antibiotic therapy.
• Antidote to overdosage or prolonged treatment with coumarin anticoagulants (e.g., warfarin).

Dosage and Administration

• **Neonates and infants**: 1–2 mg orally or intramuscularly as prophylaxis at birth or treatment in case of bleeding.
• **Adults**: 10 mg intramuscularly or orally; repeat dose as required per clinical status.
• **Warfarin reversal**: In non-urgent cases, 2.5–5 mg orally. In urgent reversal, IV route preferred under clinical supervision.
• Route of administration: Oral, intramuscular, or intravenous (off-label/emergency, with risk of anaphylaxis).

Always follow physician’s instructions. Do not self-administer intramuscular or IV injections without clinical supervision.

Contraindications

• Known hypersensitivity to phytomenadione or formulation excipients.
• Severe hepatic failure with no capacity for clotting factor synthesis.
• IV administration contraindicated unless medically justified due to rare risk of anaphylactic shock.

Side Effects

• Common: facial flushing, sweating, dizziness, taste disturbances (oral route).
• Less common: injection site pain or hematoma (IM route), mild elevation of liver enzymes.
• Rare: hypersensitivity reactions, bronchospasm, anaphylaxis (especially IV route).
• Neonates: risk of hemolysis or hyperbilirubinemia in high doses.

Precautions

• Use with caution in patients with liver disease or coagulopathies.
• Do not mix Konakion MM with other IV fluids in the same syringe or line.
• Carefully monitor INR when co-administered with anticoagulants.

Interactions

• Antagonizes the effects of vitamin K antagonists (e.g., warfarin, acenocoumarol).
• Broad-spectrum antibiotics may increase vitamin K deficiency by disrupting gut flora.
• Bile acid sequestrants (e.g., cholestyramine) reduce vitamin K absorption.
• Mineral oils, orlistat, and certain laxatives may impair absorption of fat-soluble vitamins.

Overdose and Management

Toxicity is rare due to high therapeutic index. Overdose symptoms are uncommon but may include transient flushing, hyperbilirubinemia in neonates, or hemolysis in G6PD-deficient infants. Treatment is symptomatic and supportive.

Use in Pregnancy and Lactation

Vitamin K1 does not cross the placenta efficiently; neonatal prophylaxis is essential. Konakion MM is considered safe in pregnancy at therapeutic doses. It may be used in breastfeeding women—vitamin K1 is excreted in low amounts into breast milk.

Use in Pediatrics

Neonatal prophylaxis with Konakion MM significantly reduces early and late vitamin K deficiency bleeding (VKDB). Intramuscular administration offers sustained protection, whereas oral prophylaxis may require multiple doses.

WHO Bulletin on VKDB prophylaxis

Storage

• Store in original packaging at 15–25 °C.
• Protect from light and moisture.
• Do not freeze. Keep ampoules tightly sealed until use.
• Discard after expiration date.

Clinical Studies and Evidence

A systematic review of vitamin K prophylaxis strategies showed intramuscular Konakion MM at birth prevented >95% of late VKDB compared to oral routes (Cornelissen et al., 2017). Cochrane Review

In adults on warfarin with elevated INR, low-dose oral vitamin K1 (1–2.5 mg) normalized coagulation faster than placebo without excessive clotting risk. Crowther et al., NEJM

Summary

Konakion MM 10 mg is a clinically validated formulation of vitamin K1 indicated for the prevention and treatment of deficiency states and coagulopathy. With multiple administration routes and well-established efficacy, it is considered essential for neonatal prophylaxis and adult reversal of anticoagulation. Use must be guided by medical professionals, particularly in populations at risk for liver dysfunction or bleeding disorders.

The post Konakion MM 10 mg (Vitamin K1) appeared first on MeDank Online Shop.